145 related articles for article (PubMed ID: 15701865)
1. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
2. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
Posey JA; Khazaeli MB; Bookman MA; Nowrouzi A; Grizzle WE; Thornton J; Carey DE; Lorenz JM; Sing AP; Siegall CB; LoBuglio AF; Saleh MN
Clin Cancer Res; 2002 Oct; 8(10):3092-9. PubMed ID: 12374676
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
Siegall CB
Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
[TBL] [Abstract][Full Text] [Related]
7. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
[TBL] [Abstract][Full Text] [Related]
8. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.
Friedman PN; McAndrew SJ; Gawlak SL; Chace D; Trail PA; Brown JP; Siegall CB
Cancer Res; 1993 Jan; 53(2):334-9. PubMed ID: 8417827
[TBL] [Abstract][Full Text] [Related]
9. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
11. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
Siegall CB; Liggitt D; Chace D; Tepper MA; Fell HP
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9514-8. PubMed ID: 7937798
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF
J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049
[TBL] [Abstract][Full Text] [Related]
13. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
Francisco JA; Gilliland LK; Stebbins MR; Norris NA; Ledbetter JA; Siegall CB
Cancer Res; 1995 Jul; 55(14):3099-104. PubMed ID: 7541711
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
Westwood JA; Smyth MJ; Teng MW; Moeller M; Trapani JA; Scott AM; Smyth FE; Cartwright GA; Power BE; Hönemann D; Prince HM; Darcy PK; Kershaw MH
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19051-6. PubMed ID: 16365285
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Henry CJ; McCaw DL; Turnquist SE; Tyler JW; Bravo L; Sheafor S; Straw RC; Dernell WS; Madewell BR; Jorgensen L; Scott MA; Higginbotham ML; Chun R
Clin Cancer Res; 2003 Feb; 9(2):906-11. PubMed ID: 12576466
[TBL] [Abstract][Full Text] [Related]
16. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
Siegall CB
Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
[No Abstract] [Full Text] [Related]
17. Mucin gel formed by tumorigenic squamous lung carcinoma cells has Le(a)-X oligosaccharides and excludes antibodies from underlying cells.
Stranahan PL; Howard RB; Pfenninger O; Cowen ME; Johnston MR; Pettijohn DE
Cancer Res; 1992 May; 52(10):2923-30. PubMed ID: 1581910
[TBL] [Abstract][Full Text] [Related]
18. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
19. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
20. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek).
Hay RV; Cao B; Skinner RS; Su Y; Zhao P; Gustafson MF; Qian CN; Teh BT; Knudsen BS; Resau JH; Shen S; Waters DJ; Gross MD; Vande Woude GF
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7064s-7069s. PubMed ID: 16203803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
